FIB-4 ≥1.3 is correlated with increased DKD risk in T2D, but SGLT2i therapy that lowers FIB-4 attenuates this . d. 2025;3(4):120-127. Accessed April 14, 2026. https://www.thediabzen.com/index.php/d/article/view/34